OPM announces its 2025 half-year financial results

OPM announces its 2025 half-year financial results and provides an update on its clinical developments and financial position

Dijon, France, July 31, 2025, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025.